Long-term outcomes of eltrombopag plus cyclosporine A in eltrombopag-exposed patients with glucocorticoid-resistant or -dependent primary immune thrombocytopenia: a prospective, multicenter, single-arm, phase II study with extended follow-up

Background

Primary immune thrombocytopenia (ITP) is an autoimmune disorder characterized by thrombocytopenia, and approximately 20-30% of patients are refractory to or dependent on first-line glucocorticoid therapy. Our previous prospective phase II study demonstrated promising short-term efficacy of eltrombopag (ELT) combined with cyclosporine A (CsA); however, the durability of response, long-term safety, and patterns of treatment failure remain incompletely characterized.